Reduction of oxyradical damage in biomedical applications
US5047395A · kind A · utility
27Cited by
1References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 17, 1990 |
| Grant date | Sep 10, 1991 |
| Priority date | — |
| Expiry date | Jul 17, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The biliproteins delta-bilirubin and delta-bilipeptide are useful as a cytoprotective antioxidants. Delta-bilipeptide as the term is used herein is a truncated form of delta-bilirubin in which an albumin analogue of 10-200 amino acid residues replaces the albumin portion of delta-bilirubin. Patient-administrable compositions for addition to a patient's blood to minimize oxyradical damage caused by ischemia-reperfusion injury that may result in various surgical procedures, and comprising delta-bilirubin or delta-bilipeptide, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.